CLEVELAND - A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs’ Endothelial Corneal Dystrophy (FECD), a disease ...

Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...

DelveInsight's "Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast Growth Factor-1 TTHX1114 for the regenerative treatment of ...

Bottom Line: Researchers discovered three novel genetic mutations associated with Fuchs endothelial corneal dystrophy, the most common corneal disorder requiring transplantation. Journal in Which the ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In a patient with Fuchs’ dystrophy and cataract, PK is the cornea technique of the past and ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — With an international shortage of donor corneal tissue, a procedure that uses a patient’s own ...